SELLAS Life Sciences Group Inc. (SLS), whose shares hit an all-time low of $0.50 yesterday, has a couple of catalysts to watch this year.
The company's lead product candidate, Galinpepimut-S, licensed from Memorial Sloan-Kettering Cancer Center, is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.